Last update Dec. 29, 2014

Carbocisteine

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

On latest update, no relevant published data related to excretion into breast milk were found.

It is a product that has only mild or few side-effects when used at normal dose.

The absorption from ingested mother's milk to the infant's plasma is hampered by a low oral bioavailability, with this being a reason for a nil or minimal plasma level in the infant, except in prematures or soon after birth when absorption would be higher.

Alternatives

We do not have alternatives for Carbocisteine since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 10 %
Molecular weight 179 daltons
VD 0,9 l/Kg
Tmax 1,5 - 2 hours
T1/2 2,5 - 3,1 hours

References

  1. Irish Medicines Board. Carbocisteine. Drug Summary. 2014 Full text (in our servers)
  2. AEMPS. Carbocisteina. Ficha técnica. 2012 Full text (in our servers)
  3. AEMPS. Carbocisteína. Ficha técnica. 1998 Full text (in our servers)

Total visits

54,973

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM